Proficio Capital Partners LLC Purchases Shares of 16,565 Integer Holdings Co. (NYSE:ITGR)

Proficio Capital Partners LLC acquired a new stake in shares of Integer Holdings Co. (NYSE:ITGR) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 16,565 shares of the medical equipment provider’s stock, valued at approximately $2,195,000.

Other large investors have also recently modified their holdings of the company. Blue Trust Inc. grew its holdings in Integer by 4.4% in the 4th quarter. Blue Trust Inc. now owns 1,689 shares of the medical equipment provider’s stock worth $220,000 after acquiring an additional 71 shares during the last quarter. HighTower Advisors LLC grew its stake in shares of Integer by 0.8% in the third quarter. HighTower Advisors LLC now owns 12,041 shares of the medical equipment provider’s stock worth $1,579,000 after purchasing an additional 90 shares during the last quarter. Norden Group LLC increased its holdings in Integer by 7.0% during the 4th quarter. Norden Group LLC now owns 1,668 shares of the medical equipment provider’s stock valued at $221,000 after purchasing an additional 109 shares during the period. State of New Jersey Common Pension Fund D increased its holdings in Integer by 0.9% during the 4th quarter. State of New Jersey Common Pension Fund D now owns 15,722 shares of the medical equipment provider’s stock valued at $2,083,000 after purchasing an additional 140 shares during the period. Finally, Mather Group LLC. lifted its holdings in Integer by 304.3% in the 4th quarter. Mather Group LLC. now owns 190 shares of the medical equipment provider’s stock worth $25,000 after buying an additional 143 shares during the period. Hedge funds and other institutional investors own 99.29% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have issued reports on ITGR. Wells Fargo & Company reiterated an “overweight” rating and issued a $160.00 price objective on shares of Integer in a report on Tuesday, December 3rd. Citigroup increased their price target on shares of Integer from $130.00 to $145.00 and gave the stock a “neutral” rating in a research note on Wednesday, December 11th. Truist Financial boosted their price objective on shares of Integer from $147.00 to $163.00 and gave the stock a “buy” rating in a research note on Wednesday, December 11th. KeyCorp lifted their target price on shares of Integer from $144.00 to $154.00 and gave the company an “overweight” rating in a report on Friday, January 24th. Finally, Oppenheimer downgraded Integer from an “outperform” rating to a “market perform” rating in a research note on Friday, February 21st. Two equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $149.00.

Integer Stock Down 0.4 %

Shares of ITGR stock opened at $118.87 on Wednesday. The stock’s fifty day moving average price is $133.56 and its 200 day moving average price is $132.61. Integer Holdings Co. has a 1-year low of $107.11 and a 1-year high of $146.36. The company has a market cap of $4.00 billion, a price-to-earnings ratio of 35.38, a price-to-earnings-growth ratio of 1.72 and a beta of 1.24. The company has a debt-to-equity ratio of 0.62, a current ratio of 2.95 and a quick ratio of 2.09.

Integer (NYSE:ITGR) last released its quarterly earnings data on Thursday, February 20th. The medical equipment provider reported $1.43 EPS for the quarter, missing the consensus estimate of $1.46 by ($0.03). The business had revenue of $449.50 million during the quarter, compared to analysts’ expectations of $446.28 million. Integer had a net margin of 6.92% and a return on equity of 11.65%. On average, research analysts expect that Integer Holdings Co. will post 6.01 earnings per share for the current fiscal year.

Integer Profile

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.